Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jan 20, 2011

Premium

Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene

Patent Number: 7,871,985

Filed: Dec. 10, 2008

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Factor VII gene," the patent's abstract states.


Title: c-Met siRNA Adenovirus Vectors Inhibit Cancer Cell Growth, Invasion, and Tumorigenicity

Patent Number: 7,872,117

Filed: March 28, 2005

Lead Inventor: Nariyoshi Shinomiya, Van Andel Research Institute

"Suppression of the hepatocyte growth factor/scatter factor-Met signaling pathway by targeting the Met protein tyrosine kinase was tested as strategy for suppressing tumor growth," the patent's abstract states. "RNA interference technology and adenoviruses carrying siRNA target sequences dramatically reduced Met expression in mouse, dog, and human tumor cells. Met was suppressed using Ad Met siRNA in mouse mammary tumor cells and Met-transformed cells, as well as human prostate cancer, sarcoma, glioblastoma, gastric, and ovarian cancer cells.

"Furthermore, the Ad Met siRNA infection reversed transformed cell morphology," the abstract states. "Ad Met siRNA killed cancer cells by inducing apoptosis. RNAi targeting Met suppressed HGF/SF-mediated scattering, as well as ligand-mediated invasion activity and growth of tumor cells. Met siRNA infection also abrogated downstream Met signaling to molecules such as Akt and p44/42 MAPK. Importantly, the Met siRNA-triggered apoptosis was correlated to suppressed tumorigenicity in vivo," it adds. Intra-tumoral infection with c-Met siRNA adenovirus vectors "produced significant reduction in tumor growth. Thus Met RNAi is an effective weapon for targeting Met expression and for treating c-Met [positive] cancers."


Title: siRNA and Method of Manufacture

Patent Number: 7,872,118

Filed: Sept. 6, 2007

Lead Inventor: Samuel Reich, Opko Health

The invention, the patent's abstract states, comprises "double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference. … Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided."


Title: Inhibitors of RTP801 and Their Use in Disease Treatment

Patent Number: 7,872,119

Filed: Feb. 26, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

The invention provides "novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, respiratory conditions, and hearing disorders based upon inhibition of the RTP801 gene and/or protein," the patent's abstract states.


Title: Inhibition of Versican with siRNA and Other Molecules

Application Number: 20110008366

Filed: Oct. 31, 2008

Lead Inventor: Thomas Wight, University of Washington

The invention provides "methods of treating disease or condition in a subject [by] … administering the subject a versican inhibitor in an amount effective to treat the disease or condition," the patent application's abstract states. "Example diseases or conditions include, but are not limited to, fibrotic disease such as fibrotic lung disease, restenosis such as arterial restenosis, atherosclerosis, cancer, and inflammatory disease. Compounds and compositions for carrying out such a method are also described."


Title: Compositions and Methods for Controlled Delivery of Inhibitory Ribonucleic Acids

Application Number: 20110008451

Filed: March 11, 2009

Lead Inventor: Mark Saltzman, Yale University

The invention, the patent application's abstract states, comprises "polymeric nanoparticles encapsulating inhibitory ribonucleic acids and methods of their manufacture and use. … Advantageous properties of the nanoparticles include high encapsulation efficiency of inhibitory RNAs into the nanoparticles; small size of the nanoparticles that increases cell internalization; and sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time.

"Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation," the abstract adds. "Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided."


Title: Specific GRP78 Expression-Inhibition RNAi Sequence, Medicine Thereof, and Method Thereof

Application Number: 20110008882

Filed: April 30, 2009

Lead Inventor: Ann-Joy Cheng, Chang-Gung University

The invention comprises "a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof, and a method thereof," according to the patent application's abstract. The sequence forms "a special hairpin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer."


Title: Linear Double-Stranded RNA Molecule Interfering with Different Target Genes

Application Number: 20110008885

Filed: July 7, 2008

Lead Inventor: Meehyein Kim, Mogam Biotechnology Research Institute

The invention, the patent application's abstract states, comprises "a linear double-stranded RNA molecule [with] two or more consecutively or convergently linked short interfering RNAs, each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule.

"The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell … [in which] the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA."


Title: miRNA, siRNA, and Use Thereof in Therapy

Application Number: 20110009468

Filed: Nov. 14, 2008

Lead Inventor: Irene Bozzoni, Sapienza University of Rome

The invention "relates to a mixture of molecules comprising at least one miRNA and at least one siRNA, or at least two miRNAs, or at least two siRNAs for inducing hematopoietic differentiation or for treating leukemia," the patent application's abstract states. "The miRNA is able to modulate hematopoietic differentiation and/or to act as oncosuppressor, and the siRNA is able to modulate hematopoietic differentiation or to inhibit the expression of a fusion product deriving from a chromosomic translocation associated to leukemia."


Title: Compositions and Methods of Treating Neoplasia

Application Number: 20110009469

Filed: Dec. 5, 2008

Lead Inventor: Joshua Mendell, Johns Hopkins University

The invention provides "compositions and methods featuring microRNA polynucleotides for the diagnosis, treatment, or prevention of neoplasia," the patent application's abstract states.


Title: RNAi Probes Targeting Cancer-Related Proteins

Application Number: 20110009472

Filed: July 28, 2010

Lead Inventor: Martin Gleave, University of British Columbia

The invention involves "RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma, and melanoma; [as well as] Alzheimer's disease," the patent application's abstract states. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf.

"The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; [in addition to] Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment," it adds.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.